Endocrinopathies complicating transfusion-dependent hemoglobinopathy

References

1. ↵
   1. Deborah Rund,
   2. Eliezer Rachmilewitz M

   (2005) Mb -Thalassemia. N Engl J Med 353:1135–1146.

   OpenUrlCrossRefPubMedWeb of ScienceGoogle Scholar
2. ↵
   1. Gamberini MR,
   2. Fortini M,
   3. De Sanctis V,
   4. Gilli G,
   5. Testa MR

   (2004) Diabetes mellitus and impaired glucose tolerance in thalassemia major:Incidence, prevalence, risk factors and survival in patients followed in the Ferrara Center. Pediatr Endocrinol Rev 2:285–291.

   OpenUrlPubMedGoogle Scholar
3. ↵
   1. De Sanctis V,
   2. Elsedfy H,
   3. Soliman AT,
   4. Elhakim IZ,
   5. Soliman NA,
   6. Elalaily R,
   7. et al.

   (2016) Endocrine profile of ?-thalassemia major patients followed from childhood to advanced adulthood in a tertiary care center. Indian J Endocrinol Metab 4:451–459.

   OpenUrlGoogle Scholar
4. ↵
   1. Malik S,
   2. Syed S,
   3. Ahmed N

   (2009) Complications in transfusion-dependent patients of ?-thalassemia major. PakJ Med Sci 25:678–682.

   OpenUrlGoogle Scholar
5. ↵
   1. Neufeld EJ

   (2006) Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major:New data, new questions. Blood 107:3436–3441.

   OpenUrlAbstract/FREE Full TextGoogle Scholar
6. ↵
   1. Chatterjee R,
   2. Bajoria R

   (2009) New concept in natural history and management of diabetes mellitus in thalassemia major diabetes and thalassemia. Hemoglobin 33:127–130.

   OpenUrlGoogle Scholar
7. ↵
   1. Cappellini MD,
   2. Cohen A,
   3. Eleftheriou A,
   4. Piga A,
   5. Porter J,
   6. Taher A

   (2008) Guidelines for the Clinical Management of Thalassemia (Thalassemia International Federation, Nicosia (CY)), 2nd ed.

   Google Scholar
8. ↵
   1. Moayeri H,
   2. Oloomi Z

   (2006) Prevalence of growth and puberty failure with respect to growth hormone and gonadotropins secretion in beta-thalassemia major. Arch Iran Med 9:329–334.

   OpenUrlPubMedGoogle Scholar
9. ↵
   1. Landau H,
   2. Matoth I,
   3. Landau-Cordova Z,
   4. Goldfarb A,
   5. Rachmilewitz EA,
   6. Glaser B

   (1993) Cross-sectional and longitudinal study of the pituitary-thyroid axis in patients with thalassemia major. Clin Endocrinol (Oxf) 38:55–61.

   OpenUrlPubMedGoogle Scholar
10. ↵
    1. Joshi R,
    2. Phatarpekar A

    (2013) Endocrine abnormalities in children with beta thalassemia major. Sri Lanka J. Child Health 42:81–86.

    OpenUrlGoogle Scholar
11. ↵
    1. Cario H,
    2. Holl RW,
    3. Debatin KM,
    4. Kohne E

    (2003) Insulin sensitivity and ?-cell secretion in Thalassemia major with secondary hemochromatosis:Assessment by oral glucose tolerance test. Eur J Pediatr 162:139–146.

    OpenUrlPubMedWeb of ScienceGoogle Scholar
12. ↵
    1. de Assis RA,
    2. Ribeiro AA,
    3. Kay FU,
    4. Rosemberg LA,
    5. Nomura CH,
    6. Loggetto SR,
    7. et al.

    (2012) Pancreatic iron stores assessed by magnetic resonance imaging (MRI) in beta thalassemic patients. Eur J Radiol 81:1465–1470.

    OpenUrlCrossRefPubMedGoogle Scholar
13. ↵
    1. Mahachoklertwattana P,
    2. Sirikulchayanonta V,
    3. Chuansumrit A,
    4. Karnsombat P,
    5. Choubtum L,
    6. Sriphrapradang A,
    7. et al.

    (2003) Bone histomorphometry in children and adolescents with ?-thalassemia disease:Iron-associated focal osteomalacia. J Clin Endocrinol Metab 88:3966–3972.

    OpenUrlCrossRefPubMedWeb of ScienceGoogle Scholar
14. ↵
    1. Bordbar M,
    2. Bozorgi H,
    3. Saki F,
    4. Haghpanah S,
    5. Karimi M,
    6. Bazrafshan A,
    7. et al.

    (2019) Prevalence of endocrine disorders and their associated factors in transfusion-dependent thalassemia patients:a historical cohort study in Southern Iran. J Endocrinol Invest 42:1467–1476.

    OpenUrlGoogle Scholar
15. ↵
    1. Dhouib NG,
    2. Khaled M,
    3. Ouederni M Ben,
    4. Besbes H,
    5. Kouki R,
    6. Mellouli F,
    7. et al.

    (2018) Growth and endocrine function in Tunisian thalassemia major patients. Mediterr J Hematol Infect Dis 10:e2018031.

    OpenUrlGoogle Scholar
16. ↵
    1. De Sanctis V,
    2. Elsedfy H,
    3. Soliman AT,
    4. Elhakim IZ,
    5. Kattamis C,
    6. Soliman NA,
    7. et al.

    (2016) Clinical and biochemical data of adult thalassemia major patients (TM) with multiple endocrine complications (MEC) versus TM patients with normal endocrine functions:A long-term retrospective study (40 years) in a tertiary care center in Italy. Mediterr J Hematol Infect Dis 8:e2016022.

    OpenUrlGoogle Scholar
17. ↵
    1. Bazi A,
    2. Harati H,
    3. Khosravi-Bonjar A,
    4. Rakhshani E,
    5. Delaramnasab M

    (2018) Hypothyroidism and hypoparathyroidism in thalassemia major patients:A study in Sistan and Baluchestan Province, Iran. Int J Endocrinol Metab 16:e13228.

    OpenUrlGoogle Scholar
18. ↵
    1. Belhoul KM,
    2. Bakir ML,
    3. Saned MS,
    4. Kadhim AMA,
    5. Musallam KM,
    6. Taher AT

    (2012) Serum ferritin levels and endocrinopathy in medically treated patients with ? thalassemia major. Ann Hematol 91:1107–1114.

    OpenUrlPubMedGoogle Scholar
19. ↵
    1. Isik P,
    2. Yarali N,
    3. Tavil B,
    4. Demirel F,
    5. Karacam GB,
    6. Sac RU,
    7. et al.

    (2014) Endocrinopathies in Turkish children with beta thalassemia major:Results from a single center study. Pediatr Hematol Oncol 31:607–615.

    OpenUrlGoogle Scholar
20. ↵
    1. De Sanctis V,
    2. Eleftheriou A,
    3. Malaventura C

    (2004) Thalassaemia International Federation Study Group on Growth and Endocrine Complications in Thalassemia. Prevalence of endocrine complications and short stature in patients with Thalassemia major:A multicenter study by the Thalassemia International Federation (TIF). Pediatr Endocrinol Rev 2:249–255.

    OpenUrlPubMedGoogle Scholar
21. ↵
    1. Shamshirsaz AA,
    2. Bekheirnia MR,
    3. Kamgar M,
    4. Pourzahedgilani N,
    5. Bouzari N,
    6. Habibzadeh M,
    7. et al.

    (2003) Metabolic and endocrinologic complications in beta-thalassemia major:A multicenter study in Tehran. BMC Endocr Disord 3:4.

    OpenUrlCrossRefPubMedGoogle Scholar
22. ↵
    1. Vogiatzi MG,
    2. MacKlin EA,
    3. Trachtenberg FL,
    4. Fung EB,
    5. Cheung AM,
    6. Vichinsky E,
    7. et al.

    (2009) Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassemia syndromes in North America. Br J Haematol 146:546–556.

    OpenUrlCrossRefPubMedWeb of ScienceGoogle Scholar
23. ↵
    1. Soliman A,
    2. Adel A,
    3. Wagdy M,
    4. Al Ali M,
    5. ElMulla N

    (2008) Calcium homeostasis in 40 adolescents with beta-thalassemia major:A case-control study of the effects of intramuscular injection of a megadose of cholecalciferol. Pediatr Endocrinol Rev 6:149–154.

    OpenUrlPubMedGoogle Scholar
24. ↵
    1. Mohammadian S,
    2. Bazrafshan HR,
    3. Sadeghi-Nejad A

    (2003) Endocrine gland abnormalities in thalassemia major:a brief review. J Pediatr Endocrinol Metab 16:957–964.

    OpenUrlPubMedWeb of ScienceGoogle Scholar